Researchers still need to learn whether THC/CBD helps people with mild cognitive impairment at all, because the LiBBY trial tested only hospice-eligible late-stage dementia. Mild cognitive impairment means early thinking changes without loss of daily independence, and no one at that stage joined LiBBY. The Phase 2 LiBBY trial randomized 120 hospice-eligible people with Alzheimer's or other dementias and agitation to placebo or oral THC/CBD oil for 12 weeks. Active treatment was 2 mg THC plus 100 mg CBD in digestible oil, taken twice daily.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who did LiBBY actually enroll?
- What changed on the study oil?
- Why should MCI families wait?
- What must MCI studies test next?
Who did LiBBY actually enroll?
The trial enrolled only advanced dementia meeting DSM-5 major neurocognitive disorder plus hospice, FAST stage 6d, or ADEPT criteria, as listed in the Veeva trial record for NCT05644262 described by Veeva. That means daily care needs were high. Agitation occurred in an end-of-life context.
People with mild cognitive impairment live in a different clinical place. Memory lapses may disrupt plans, yet dressing, eating, and decisions remain self-managed. Triggers, risks, and treatment goals differ sharply from late-stage care.
What changed on the study oil?
The test oil, called T2:C100, paired a small THC dose with a larger CBD dose in a supervised formula. Matching placebo controlled the comparison over 12 weeks. Agitation scores fell 10.61 points on THC/CBD versus 4.35 on placebo at week 2, according to MIMS reporting of Dr.
Jacobo Mintzer's AAIC 2026 presentation from the Medical University of South Carolina. Benefit persisted through 12 weeks. Clinician-rated global improvement reached 87.2% on THC/CBD versus 23.6% on placebo at week 12.
Why should MCI families wait?
Safety data came from a frail end-of-life group. Overall adverse events were similar, but serious events were higher on THC/CBD, at 23.3% versus 11.9%, driven by infections, with more deaths at 13.1% versus 5.1%, according to NeurologyLive coverage of the 12-week results from NeurologyLive. Those numbers do not predict risk for healthier, community-dwelling adults.
The result also ties to one purified, supervised formulation and dose. Dispensary or over-the-counter cannabis products are not substitutes. Families can protect an MCI care plan with practical steps:.
- track agitation triggers, sleep, pain, and new drugs for the clinic visit
- ask the care team to review mood, behavior supports, and caregiver strain first
- do not start, borrow, or swap cannabis oils based on late-stage results
What must MCI studies test next?
Future trials must define agitation in early impairment separately from late-stage restlessness. Verbal outbursts, anxiety at appointments, and withdrawal differ from end-of-life distress. Measurement tools need validation for that milder range.
Dose, duration, thinking effects, driving safety, drug interactions, and caregiver outcomes also need direct testing in MCI. A low dose that calms advanced agitation could still impair attention, balance, or memory earlier in the course. Bring a dated list of episodes, sleep changes, and medications to each brain-health visit.
You Might Also Like
- Dementia With Multiple Etiologies in the 2026 NIA Report: Why the Findings May Not Change Care Yet for People With Mild Cognitive Impairment
- Medication Safety and Deprescribing in WHO’s 2026 Delirium Work: Research Participation Questions for People With Mild Cognitive Impairment
- Injection Training for the 2026 At-Home Leqembi Regimen: What the News Means for People With Mild Cognitive Impairment
